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Amino acid sequences of 285 and 286 residues, respectively, were deduced for mouse and human BM-40 from cDNA 
clones isolated from expression libraries. The sequences showed 92% identity and were also essentially identical to those 
of bone osteonectin and of the parietal endoderm protein SPARC. About 60% of the mouse BM-40 sequence was con- 
firmed by Edman degradation. Two of the seven disulfide bonds were localized which apparently separate two distinct 
domains of mouse BM-40. 
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1. INTRODUCTION 
Basement membranes represent unique ex- 
tracellular matrices being composed of several 
distinct proteins [ 1,2]. Among these components is 
a 40 kDa glycoprotein, BM-40, which was 
originally purified from the mouse Engelbreth- 
Holm-Swarm (EHS) tumor and shown to be pre- 
sent in various tissues and cell culture media [3]. 
The protein could be released from the matrix by 
chelating agents, demonstrating that divalent cat- 
ions are involved in its repertoire of interactions 
[4]. Subsequent observations then established that 
BM-40 binds several Ca2+ cooperatively, with a Kd 
of l-10 yM which is accompanied by an increase 
in a-helical conformation [5]. How these structural 
changes are reflected by distinct biological func- 
tions still remains to be identified. 
Partial sequence analysis of BM-40 [4] indicated 
identity to the mouse parietal endoderm protein 
SPARC, the protein sequence of which had been 
deduced from cDNA sequences [6]. Analysis of the 
distribution of mRNA for SPARC revealed that it 
is not restricted to basement membrane-rich 
regions of mouse embryonic tissues [7,8]. Recent 
studies demonstrated in addition a high sequence 
homology to bovine osteonectin [9] which was 
previously considered to be a bone-specific protein 
with binding activities for collagen, calcium and 
hydroxyapatite [ 10,111. Apparently, the proteins 
referred to as BM-40, SPARC or osteonectin are 
distributed in quite diverse compartments of con- 
nective tissue, but represent very similar or even 
identical gene products. In order to substantiate 
this possibility we have now completed the se- 
quence of mouse BM-40 and compared it with a 
similar sequence deduced from human cDNA 
clones. In addition, we have localized two disulfide 
bonds in BM-40, which lends support to previous 
predictions [5,9] on the domain structure of the 
protein. 
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FRG 2. MATERIALS AND METHODS 
The nucleotide sequence presented here has been submitted to A cDNA library in the hgtll vector of 6 x 10’ independent 
the EMBL/GenBank database under the accession number clones with an average size of 0.8 kb was prepared for us from 
YOO755 mouse EHS tumor mRNA by Clontech Laboratories (Palo 
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Alto, CA). About 5 x lo5 clones were screened with polyclonal 
antibodies to mouse BM-40 [3] following previously described 
procedures [12,13]. The clones were plaque-purified, the inserts 
released by EcoRI digestion and subcloned into pUC19 [14]. 
The same and another hgtl 1 library from human placenta 
(Clontech) were screened with murine BM-40 probes which 
were “P-nick-translated (Amersham nick-translation kit) 
following the supplier’s protocol. The screening followed stan- 
dard procedures [ 151. Positive clones were plaque-purified and 
subcloned into pUCI9. Nucleotide sequences of the 3’. and 
5 ‘-ends of cloned inserts were determined by the dideoxy chain- 
termination method [16] using oligonucleotide primers for the 
pUC19 vector (US Biochemicals, Cleveland, OH). 
Total RNA was prepared from 4 M guanidine isothiocyanate 
extracts of the EHS tumor and cultured human fibroblasts [14], 
electrophoresed on 1% formaldehyde polyacrylamide gels [15] 
and transferred to Gene Screen membranes (New England 
Nuclear, Boston, MA). Northern blot hybridization with nick- 
translated murine and human cDNA probes followed standard 
protocols [IS]. Runs were calibrated with ADNA digested with 
Hind111 (Boehringer, Mannheim). 
Purified, non-reduced mouse BM-40 was cleaved with SV8 
protease or TPCK-trypsin [4]. Digests were separated by 
molecular-sieve and reversed-phase chromatography and 
purified peptides subjected to Edman degradation as described 
[4,121. 
Fig. I. Northern blot hybridization of human fibroblast (A) and 
mouse EHS tumor (B) RNA to human or mouse BM-40 cDNA 
probes, respectively. Each lane was loaded with 1 pg total 
RNA. The nick-translated probes corresponded to the 1300 
nucleotide human or 600 nucleotide mouse inserts. Open 
triangles show the mRNA bands identified. Numbers refer to 
3. RESULTS 
Screening of an expression library prepared 
from the mouse EHS tumor with rabbit antiserum 
against mouse BM-40 yielded eight positive clones. 
All clones were identical as shown by sequencing 
and EcoRI digestion which resulted in inserts of 
about 600 nucleotides from the 3 ’ -end and of 300 
nucleotides from the 5 ‘-end. The same internal 
EcoRI recognition site is also present in mouse 
SPARC cDNA [6]. Screening with the 300 
nucleotide probe yielded another overlapping 300 
nucleotide clone which covered the 5 ‘-end of the 
coding region of mouse BM-40. Several more 
cDNA clones were obtained from a human placen- 
ta library by using the various mouse probes for 
screening. They included a single 500 nucleotide 
clone from the 5’-end, and several 1300 nucleotide 
clones from the 3 ’ -end of human BM-40 mRNA. 
ter band was not examined further. 
Northern blot hybridization of mouse EHS 
tumor RNA with two different mouse probes 
demonstrated a single 2.2 kb band (fig.lB) as 
previously found for mouse SPARC mRNA [6]. 
Examination of human fibroblast RNA with the 
corresponding human probes identified the same 
major mRNA band but in addition a weak reaction 
with a 3.0 kb band (fig. 1A). The nature of the lat- 
Nucleotide sequences were determined from 
both inserts which overlapped at the EcoRI site 
(fig.2). The human sequence showed an open 
reading frame of 909 nucleotides encoding 17 
amino acid residues of a signal peptide and 286 
residues of the BM-40 protein. The N-terminal 36 
amino acid residues of human BM-40 were iden- 
tical to those reported for human osteonectin [9] 
except for two, Ser-Val in position 25-26 (fig.2), 
which had been determined as Pro-Thr in os- 
teonectin. The mouse sequence coding for BM-40 
showed 89% identity at the nucleotide and 92% 
identity at the amino acid level compared to the 
human sequence. The mouse BM-40 sequence was 
also identical to that of mouse SPARC [6] with 
two exceptions (fig.2). 
About 60% of the deduced mouse sequence was 
confirmed by Edman degradation of peptides 
generated from BM-40 by SV8 protease and tryp- 
sin (fig.2). The only difference was found at amino 
acid position 271 where a Gly instead of Ser was 
found by Edman degradation which was also the 
position at variance between BM-40 and SPARC 
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Fig.2. Nucleotide sequence and deduced amino acid sequence of cDNA clones encoding human BM-40. Nucleotide and amino acid 
substitutions within the corresponding murine sequence are shown above and below the human sequence. Sequences confirmed by 
Edman degradation of mouse BM-40 peptides are underlined. Cysteines are encircled and NXT putative carbohydrate acceptor sites 
are shown in boxes. An arrowhead denotes the cleavage site for the signal peptide. Numbering is for the human sequence; the mouse 
amino acid sequence is one residue less after position Il. Two nucleotide positions (199,896) of mouse BM-40 are at variance with 
SPARC cDNA [6]. Two more nucleotides (nos 200,201) were ambiguous and were taken from the SPARC sequence. 
cDNA sequences (see above). Trypsin cleavage was Cys-11 and -12 (peptide T4). Peptide T5 occurred 
also used to identify several disulfide-bonded pep- either with a single sequence FFETC- 
tides. A large fragment containing S-10 of the 14 DLDNDKYIALEEXA(X) or as a variant with an 
cysteine residues could be separated from smaller additional cleavage of the KY bond. Peptide T4 
peptides and showed multiple N-terminal se- showed only a double sequence interpreted as 
quences. Two more peptides contained cysteines YIAPCLDSELTEFPLR and APLIPMEHCTTR 
and allowed the localization of disulfide bonds be- according to the cDNA sequences (fig.2). Since 
tween Cys-13 and -14 (peptide TS) and between only single cysteine residues were present in the 
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Fig.3. Schematic domain structure of BM-40 as proposed for 
SPARUosteonectin [5,9] and positions of cysteines (C) and 
some disulfide bonds. Those determined by Edman degradation 
are denoted by black circles. Bonds predicted from the trypsin 
inhibitor homology ([9,18]; see text) are connected by black 
bars. Numbering of cysteines follows the mouse sequence 
(fig.2). 
predicted tryptic peptides there was no ambiguity 
in assigning the disulfide bonds. 
4. DISCUSSION 
Complete amino acid sequences deduced mainly 
from cDNA clones demonstrated a high degree of 
identity (92%) between human and mouse BM-40. 
Major differences were noted close to the N- 
terminus including a Glu in position 12 of human 
BM-40 which is deleted in the mouse sequence, 
making both proteins slightly different in size (286 
vs 285 residues, respectively). The human sequence 
also contains two Asn residues in typical car- 
bohydrate acceptor sequences (positions 71 and 99, 
fig.2) while only the latter is conserved in the 
mouse. A further Asp/Glu substitution (position 
267) is located within the loop of the EF-hand do- 
main (fig.3), a presumed Ca2+-binding site, but is 
not in conflict with the consensus sequence motif 
[5]. All 14 Cys residues are, however, invariant in 
the sequences, indicating identical folding patterns 
for the two proteins. 
Our data also demonstrate identity of the mouse 
proteins BM-40 and SPARC [6] which was 
predicted from previous partial sequence analysis 
[4]. Single nucleotide differences between both se- 
quences are presumably due to a mismatch and 
were not confirmed by Edman degradation. A high 
level of homology was also found for the bovine 
osteonectin sequence which was recently deduced 
from bone cDNA [9]. Human BM-40 differs by 
two successive non-conservative amino substitu- 
tions (see above) from the N-terminal sequence of 
human osteonectin as was determined by Edman 
degradation [9]. This difference is located beyond 
the region of high interspecies sequence variability 
which is encoded within a single exon of the os- 
teonectin gene [17]. This might indicate that the 
BM-40 and osteonectin sequences are polymorphic 
variants or encoded by different, yet closely related 
genes. 
Analyses of the SPARC [5] and osteonectin [9] 
sequences have led to the prediction of four pro- 
tein domains (fig.3), with domains I and IV con- 
taining potential Ca2+-binding sites. Our data on 
disulfide bond localization show in fact that the 
last two pairs of cysteine residues in mouse BM-40 
stabilize both the a-helical domain III and the EF- 
hand domain IV. The latter bond was predicted 
from a comparison with other Ca2+-binding pro- 
teins [5]. Six further Cys residues show homology 
to pancreatic trypsin inhibitor, ovomucoid and 
other protease inhibitors [9,18] and are likely to 
stabilize a similar disulfide-bonded structure 
(fig.3). These six cysteines together with the re- 
maining four endow domain II with a compact 
structure which can be only incompletely cleaved 
by trypsin. Osteonectin contains an additional Cys 
located within the a-helical domain III [9] which is 
missing in BM-40/SPARC. This residue is unlikely 
to participate in intramolecular disulfide bonds but 
may be involved in other functions of the protein. 
Further sequence analyses may show whether this 
particular residue is unique to bone osteonectins. 
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